Patient Case 3: A 79-Year-Old Female With IgG Kappa Multiple Myeloma

GCF012F may show promising activity in relapsed and refractory multiple myeloma, according to an expert from Shanghai Chang Zheng Hospital.

Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.

Numerous patients with heavily pretreated relapsed/refractory multiple myeloma responded following treatment with talquetamab and daratumumab.

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

A phase 1 trial continued to show positive responses when PHE885 was used in patients with relapsed/refractory multiple myeloma.

Results from the phase 1b RedirecTT-1 study show acceptable efficacy and safety when teclistamab plus talquetamab was given to patients with relapsed/refractory multiple myeloma.